BRPI0909817A2 - uso de células-tronco mesenquimais para tratamento de doenças e distúrbios genéticos - Google Patents

uso de células-tronco mesenquimais para tratamento de doenças e distúrbios genéticos

Info

Publication number
BRPI0909817A2
BRPI0909817A2 BRPI0909817A BRPI0909817A BRPI0909817A2 BR PI0909817 A2 BRPI0909817 A2 BR PI0909817A2 BR PI0909817 A BRPI0909817 A BR PI0909817A BR PI0909817 A BRPI0909817 A BR PI0909817A BR PI0909817 A2 BRPI0909817 A2 BR PI0909817A2
Authority
BR
Brazil
Prior art keywords
disorders
stem cells
mesenchymal stem
treat genetic
genetic disorders
Prior art date
Application number
BRPI0909817A
Other languages
English (en)
Inventor
Danilkovitch Alla
r mills Charles
R Varney Timothy
Original Assignee
Osiris Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics filed Critical Osiris Therapeutics
Publication of BRPI0909817A2 publication Critical patent/BRPI0909817A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
BRPI0909817A 2008-03-05 2009-03-04 uso de células-tronco mesenquimais para tratamento de doenças e distúrbios genéticos BRPI0909817A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/042,487 US20080286249A1 (en) 2006-01-12 2008-03-05 Use of mesenchymal stem cells for treating genetic diseases and disorders
PCT/US2009/001390 WO2009111030A1 (en) 2008-03-05 2009-03-04 Use of mesenchymal stem cells for treating genetic diseases and disorders

Publications (1)

Publication Number Publication Date
BRPI0909817A2 true BRPI0909817A2 (pt) 2017-06-13

Family

ID=40635808

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909817A BRPI0909817A2 (pt) 2008-03-05 2009-03-04 uso de células-tronco mesenquimais para tratamento de doenças e distúrbios genéticos

Country Status (10)

Country Link
US (8) US20080286249A1 (pt)
EP (1) EP2262513A1 (pt)
JP (1) JP6037597B2 (pt)
CN (1) CN102014936A (pt)
AU (1) AU2009220137A1 (pt)
BR (1) BRPI0909817A2 (pt)
CA (1) CA2717498A1 (pt)
MX (1) MX2010009767A (pt)
NZ (1) NZ587809A (pt)
WO (1) WO2009111030A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2708933T3 (es) 2005-12-29 2019-04-12 Celularity Inc Poblaciones de células madre placentarias
DK2330889T3 (en) 2008-08-20 2017-01-30 Anthrogenesis Corp Improved cell composition and process for making the same
HRP20130812T1 (en) 2008-08-22 2013-09-30 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
SG190659A1 (en) 2008-09-02 2013-06-28 Pluristem Ltd Adherent cells from placenta tissue and use thereof in therapy
CN102282252B (zh) 2008-11-19 2017-07-04 人类起源公司 羊膜来源的贴壁细胞
CN102639694B (zh) * 2009-11-27 2015-05-27 斯蒂姆普优提克斯个人研究有限公司 制备间充质干细胞、组合物和其试剂盒的方法
US20110142805A1 (en) * 2009-12-15 2011-06-16 Advanced Technologies And Regenerative Medicine, Llc Method of renal repair and regeneration and the treatment of diabetic nephropathy
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
AU2011352036A1 (en) 2010-12-31 2013-07-18 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
WO2012127320A1 (en) 2011-03-22 2012-09-27 Pluristem Ltd. Methods for treating radiation or chemical injury
CN104220081A (zh) 2011-06-01 2014-12-17 人类起源公司 利用胎盘干细胞治疗疼痛
WO2013055476A1 (en) * 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
CN103183736A (zh) * 2011-12-27 2013-07-03 北京和信非凡生物技术有限公司 一种抗clcn7蛋白的单克隆抗体及其应用
US20150246072A1 (en) * 2012-09-04 2015-09-03 Anthrogenesis Corporation Methods of tissue generation
WO2014087658A1 (en) * 2012-12-07 2014-06-12 Kuraray Co., Ltd. Method of cell fusion and fusion cells
US20140271568A1 (en) 2013-03-12 2014-09-18 Hawking Biological Technology Co., Ltd Method and kit for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, cxc chemokine receptor 4, and/or immune regulatory factor of stem cell
CN104042606B (zh) * 2013-03-12 2017-05-24 国钦生物科技股份有限公司 苯酞化合物的应用
US11318166B2 (en) 2014-06-04 2022-05-03 Cedars-Sinai Medical Center Method for non surgical repair of vertebral compression fractures
CN104726496B (zh) * 2015-03-27 2017-07-07 中国科学院生物物理研究所 携带人类成年早衰症基因突变的多能干细胞及制备方法
CA2988137C (en) 2015-06-11 2021-01-26 Maria Siemionow Muscular dystrophy chimeric cells and method for treating muscular dystrophies
US11253629B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Bone gel sheet composition and method of manufacture
US9788950B1 (en) 2016-04-22 2017-10-17 Vivex Biomedical, Inc. Cohesive bone composition
US11253630B2 (en) 2016-04-22 2022-02-22 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
US10463767B2 (en) 2016-04-22 2019-11-05 Vivex Biologics Group, Inc. Moldable bone composition
US10596298B2 (en) 2016-04-22 2020-03-24 Vivex Biologics Group, Inc. Malleable demineralized bone composition and method of manufacture
CN109952371A (zh) 2016-11-15 2019-06-28 株式会社钟化 包含来自胎儿附属物的间充质系干细胞的细胞群、其制备方法、以及医药组合物
EP3717635B1 (en) * 2017-11-28 2025-10-22 The Board of Trustees of the University of Illinois Multi-chimeric cell and therapy for transplantation and treatment of immune deficiencies and genetic disorders
WO2019132026A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
WO2020251020A1 (ja) 2019-06-14 2020-12-17 株式会社カネカ 間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法
JP2026509434A (ja) * 2023-03-06 2026-03-19 リンイー・バイオテック・カンパニー・リミテッド 切断型ａｔｐ７ｂ及びその使用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5635156A (en) * 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6962698B1 (en) * 1998-02-17 2005-11-08 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
ES2237089T3 (es) * 1998-03-13 2005-07-16 Osiris Therapeutics, Inc. Usos para celulas madre mesenquimatosas humanas no autologas.
ES2258329T3 (es) * 1998-03-18 2006-08-16 Osiris Therapeutics, Inc. Celulas madre mesenquimaticas para la prevencion y tratamiento de respuestas inmunes en trasplantes.
US7544509B2 (en) * 2000-01-24 2009-06-09 Mcgill University Method for preparing stem cell preparations
KR20040023724A (ko) * 2001-08-07 2004-03-18 기린 비루 가부시키가이샤 조혈 간세포의 제조법
JP3978179B2 (ja) * 2001-09-20 2007-09-19 アンチキャンサー インコーポレーテッド ネスチンを発現する毛包幹細胞
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US20030157110A1 (en) * 2002-01-07 2003-08-21 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
ATE421328T1 (de) * 2002-02-22 2009-02-15 Intracel Recources Llc Sterile immunogene nicht-tumorigene tumorzell- zusammensetzungen und verfahren
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
DE10242337A1 (de) * 2002-09-09 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Isolierung und/oder Identifizierung neuronaler Stammzellen und Verfahren zur Isolierung und/oder Identifizierung neuronaler Vorläuferzellen
GB0304030D0 (en) * 2003-02-21 2003-03-26 King S College London Teeth
AU2004242091C1 (en) * 2003-05-07 2009-12-24 La Jolla Institute For Molecular Medicine Administration of hyaluronic acid to enhance the function of transplanted stem cells
WO2005010524A1 (en) * 2003-06-04 2005-02-03 Curis, Inc. Stem cell-based methods for identifying and characterizing agents
ES2564044T3 (es) * 2003-06-27 2016-03-17 DePuy Synthes Products, Inc. Células posparto derivadas de tejido del cordón umbilical y métodos de preparación y uso de las mismas
US20050256077A1 (en) * 2004-03-30 2005-11-17 Henning Susan J Gastrointestinal stem cells and uses thereof
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders

Also Published As

Publication number Publication date
CN102014936A (zh) 2011-04-13
US20100330052A1 (en) 2010-12-30
US20140030235A1 (en) 2014-01-30
MX2010009767A (es) 2010-09-28
US20110177045A1 (en) 2011-07-21
JP2011514901A (ja) 2011-05-12
US20130121975A1 (en) 2013-05-16
AU2009220137A1 (en) 2009-09-11
US20100291047A1 (en) 2010-11-18
US20140322180A1 (en) 2014-10-30
JP6037597B2 (ja) 2016-12-07
US20080286249A1 (en) 2008-11-20
WO2009111030A1 (en) 2009-09-11
NZ587809A (en) 2012-08-31
US20120263687A1 (en) 2012-10-18
CA2717498A1 (en) 2009-09-11
EP2262513A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
BRPI1013771A2 (pt) "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."
DK2223696T3 (da) Mesenkymale CD34- stamceller til anvendelse i sårhelings-genterapi
HRP20182135T1 (hr) Pripravci za i postupci liječenja poremećaja povezanih s ige
BRPI0917993A2 (pt) composições de célula-tronco mesenquimal purificada e métodos de purificação de composições de célula-tronco mesenquimal purificda.
EP2315829A4 (en) INDUCED PLURIPOTENTIAL STEM CELLS
LT2494039T (lt) Ląstelių perprogramavimo būdai ir jų panaudojimas
IL216902B (en) Methods for culturing stem and progentitor cells
EP2414510A4 (en) INDUCED PLURIPOTENTIAL STEM CELLS
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
BRPI1011655A2 (pt) uso de lcat para tratar anemia e disfunção de glóbulos vermelhos
ZA200805610B (en) Use of mesenchymal stem cells for treating genetic diseases and disorders
BRPI0921726A2 (pt) método e dispositivo para ativar células tronco
EP2419511A4 (en) TARGETED INTEGRATION IN STEM CELLS
DK2620493T3 (da) Mesenkymale stamceller til behandling af CNS-sygdomme
CO6900138A2 (es) Nuevos sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma
BRPI0814425A2 (pt) Diferenciação de células-tronco embrionárias humanas
PT2785359T (pt) Células estromais mesenquimatosas e usos relacionados com as mesmas
GB0814249D0 (en) Uses of mesenchymal stem cells
FI20096288A0 (fi) Formulations and methods for culturing stem cells
PT2496691T (pt) Composições de nucleases terapêuticas e métodos
SE0950586L (sv) Förbättrad odling av stamceller
CY2017021I1 (el) Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9
BRPI0913925A2 (pt) Diferenciação de células-tronco pluripotentes
EP2456858A4 (en) DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
EP2370445A4 (en) STEM CELL CULTURES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25B Requested transfer of rights rejected

Owner name: OSIRIS THERAPEUTICS (US)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 860140039720 DE 27/03/2014 EM VIRTUDE DO DESPACHO PUBLICADO NA RPI NO 2468 DE 24/04/2018.

Owner name: OSIRIS THERAPEUTICS (US)